Validated drug discovery assay overcomes previous challenges in targeting NaV1.9 ion channels for chronic pain signalling
Completes unique suite of rapid, scalable pain-related sodium channel assays and services to accelerate hit-to-lead and lead optimisation programmes
Cambridge, UK, 28 April 2025: Metrion Biosciences (“Metrion”), the specialist preclinical contract research organisation (CRO) and a global leader in ion channel services, today announced the launch of its validated, high-throughput NaV1.9 screening assay to advance discovery and development of novel pain therapeutics.…
Pioneer Group, leading developer of life science ecosystems, integrating infrastructure, investment, and venture support, and ZEISS, a global leader in optical and optoelectronic technology, have unveiled a strategic partnership.
Through the partnership, which kicks off at Victoria House in London, but is set to expand across the wider Pioneer network, ZEISS will empower tenant researchers with advanced imaging technology for biotech and pharmaceutical innovations, help to foster a collaborative ecosystem that enables startups and research groups to leverage ZEISS expertise and technology,…
The April edition of our People Pathways newsletter is available to read here!
Featuring: ✅ One Nucleus upcoming courses✅ Blog including key takeaways from the 31 March skills roundtable✅ Cyber awareness survey✅ UCL Summer Courses
Partnership to validate and promote the application of CN Bio’s PhysioMimix technology, with future opportunities for novel application and assay development
Cambridge, UK, 24 April 2025: CN Bio, a leading provider of Organ-on-a-chip systems and solutions that accelerate drug discovery and development workflows, today announced the establishment of a strategic partnership with Pharmaron, a premier R&D service provider for the life sciences industry. Under the agreement, Pharmaron will validate CN Bio’s PhysioMimix® technologyacross existing applications and collaborate…
In-licensing transforms Mosaic from a research and platform company to a clinical-stage oncology business
Mosaic will develop proprietary, targeted combination products, supported by proprietary biomarkers, to realise the full potential of the assets
As part of the agreement Astex has taken an equity stake in Mosaic
Cambridge, UK, 24 April 2025 – Mosaic Therapeutics, Ltd (‘Mosaic’, or ‘the Company’) a targeted oncology therapeutics company dedicated to resolving cancer’s complexity with new combination therapies for patients, today announces the in-licensing of two clinical-stage oncology…
Amsbio has launched a new range of Deubiquitinating (DUB) enzyme assay kits supplied in a convenient and easy-to-use 96-well assay format. With minimal setup required and no need for substrate preparation, these ready-to-use kits accelerate routine DUB activity assays without compromising data quality.
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. The DUB enzyme family contains around 100 proteins that remove ubiquitin from a variety of substrates. Widely…
Reflects the potential of EvoLiver test to improve early liver cancer detection among high-risk patients
EvoLiver leverages Mursla Bio’s platform based on organ-specific extracellular vesicles circulating in blood
Breakthrough status provides expedited review and closer collaboration with the FDA, ultimately enabling broader market reach and commercial adoption
Cambridge, UK, and Boston MA, USA, 23 April 2025: Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the power of Dynamic Biopsy technology,…
• Focus on high value R&D underpinned by Arestat™ technology and Company expertise positions Arecor for significant future growth and success• Significant advancements in diabetes portfolio with positive progress towards strategic partnership for AT278• Potential to unlock significant value through innovation in the oral delivery of peptides• Growing revenue stream from AT220 global royalties• Expansion of partnership portfolio and licensing of Arestat™-enhanced products•…
Armed with a potent membrane protein production arsenal, Creative Biolabs stands by to lend a helping hand to researchers across the world so as to avoid the "doom loop" that has haunted membrane protein research for decades.Step aside AI and CRISPR—there's a new darling in biotech—membrane proteins, the cell gatekeepers behind 60% of all drug targets, are getting their time in the spotlight as breakthroughs in structural biology and drug design enter the mix and stimulate a frenzy of innovations. Creative Biolabs provides satisfactory membrane protein products and relatively flexible options…
Leading global drug development consultancy Boyds has strengthened its team with the appointment of senior regulatory affairs professional Kelsey Lenoch.
Kelsey joins Boyds as Associate Director, Regulatory Affairs in the US, bringing with her 15 years of experience in clinical research and drug development.
Previously, Kelsey was Senior Manager, Regulatory Affairs at Usona Institute, a non-profit medical research organization in Madison, Wisconsin, USA, working across both regulatory strategy and CMC development, supporting the clinical development of multiple psychedelic drugs. Prior to…